174 related articles for article (PubMed ID: 17607370)
1. Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status.
Badalian G; Barbai T; Rásó E; Derecskei K; Szendrôi M; Tímár J
Pathol Oncol Res; 2007; 13(2):99-104. PubMed ID: 17607370
[TBL] [Abstract][Full Text] [Related]
2. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
Han C; Zou H; Ma J; Zhou Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
[TBL] [Abstract][Full Text] [Related]
4. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
5. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?
Hendriks LE; Smit EF; Vosse BA; Mellema WW; Heideman DA; Bootsma GP; Westenend M; Pitz C; de Vries GJ; Houben R; Grünberg K; Bendek M; Speel EJ; Dingemans AM
Lung Cancer; 2014 Apr; 84(1):86-91. PubMed ID: 24529684
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer.
Wang S; Wang Z
Clin Oncol (R Coll Radiol); 2015 Jan; 27(1):30-9. PubMed ID: 25445553
[TBL] [Abstract][Full Text] [Related]
7. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.
Yang CH; Chou HC; Fu YN; Yeh CL; Cheng HW; Chang IC; Liu KJ; Chang GC; Tsai TF; Tsai SF; Liu HP; Wu YC; Chen YT; Huang SF; Chen YR
Biochim Biophys Acta; 2015 Jul; 1852(7):1540-9. PubMed ID: 25912735
[TBL] [Abstract][Full Text] [Related]
8. Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.
Taverna S; Pucci M; Giallombardo M; Di Bella MA; Santarpia M; Reclusa P; Gil-Bazo I; Rolfo C; Alessandro R
Sci Rep; 2017 Jun; 7(1):3170. PubMed ID: 28600504
[TBL] [Abstract][Full Text] [Related]
9. Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma--The Results of Three Year Retrospective Analysis.
Bittner N; Balikó Z; Sárosi V; László T; Tóth E; Kásler M; Géczi L
Pathol Oncol Res; 2015 Sep; 21(4):1217-21. PubMed ID: 26055897
[TBL] [Abstract][Full Text] [Related]
10. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Han SW; Kim TY; Jeon YK; Hwang PG; Im SA; Lee KH; Kim JH; Kim DW; Heo DS; Kim NK; Chung DH; Bang YJ
Clin Cancer Res; 2006 Apr; 12(8):2538-44. PubMed ID: 16638863
[TBL] [Abstract][Full Text] [Related]
11. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
[TBL] [Abstract][Full Text] [Related]
13. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
Dormieux A; Mezquita L; Cournede PH; Remon J; Tazdait M; Lacroix L; Rouleau E; Adam J; Bluthgen MV; Facchinetti F; Tselikas L; Aboubakar F; Naltet C; Lavaud P; Gazzah A; Le Pechoux C; Lassau N; Balleyguier C; Planchard D; Besse B; Caramella C
Eur Radiol; 2020 Sep; 30(9):5021-5028. PubMed ID: 32323012
[TBL] [Abstract][Full Text] [Related]
14. The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.
Konishi T; Huang CL; Adachi M; Taki T; Inufusa H; Kodama K; Kohno N; Miyake M
Int J Oncol; 2000 Mar; 16(3):501-11. PubMed ID: 10675482
[TBL] [Abstract][Full Text] [Related]
15. Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis.
Lee CC; Soon YY; Tan CL; Koh WY; Leong CN; Tey JCS; Tham IWK
PLoS One; 2019; 14(6):e0218414. PubMed ID: 31216329
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor mutations should be considered as a prognostic factor for survival of patients with pathological fractures or painful bone metastases from non-small cell lung cancer.
Willeumier JJ; van der Hoeven NM; Bollen L; Willems LN; Fiocco M; van der Linden YM; Dijkstra PD
Bone Joint J; 2017 Apr; 99-B(4):516-521. PubMed ID: 28385942
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.
Daniele L; Cassoni P; Bacillo E; Cappia S; Righi L; Volante M; Tondat F; Inghirami G; Sapino A; Scagliotti GV; Papotti M; Novello S
J Thorac Oncol; 2009 Jun; 4(6):684-8. PubMed ID: 19404216
[TBL] [Abstract][Full Text] [Related]
18. [Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer].
Fang Q; Zhang L; Wang S; Ou W
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):518-22. PubMed ID: 21645456
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma.
Hsieh ET; Shepherd FA; Tsao MS
Lung Cancer; 2000 Aug; 29(2):151-7. PubMed ID: 10963846
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
